ChemoMetec
kr 550.50Change from previous close: +6.07%Absolute change: +kr 31.50
Valuation
Data as of October 4, 2026
Valuation multiples
- Market cap
- kr 9.45B
- Enterprise value
- kr 9.18B
- P/E (trailing 12 months)
- 47.4
- Forward P/E
- 33.8
- Price/book
- 13.1
- Price/sales
- 18.5
- EV/EBITDA
- 34.5
- EV/revenue
- 18.0
Profitability and growth
- Gross margin
- 95.1%
- Operating margin
- 49.8%
- Net margin
- 39.5%
- ROE
- 28.6%
- ROA
- 18.5%
- Revenue growth (year over year)
- 7.4%
- Earnings growth (year over year)
- 51.3%
Financial health
- Total cash
- kr 293.56M
- Total debt
- kr 4.59M
- Debt/equity
- 0.01
- Current ratio
- 4.09
- Quick ratio
- 3.06
Dividends
- Annual dividend per share
- kr 7.00
- Dividend yield
- 1.3%
- Payout ratio
- 60.3%
- Ex-dividend date
- October 10, 2025
Analysts and estimates
- Average price target
- kr 635.00
- Median price target
- kr 640.00
- High price target
- kr 715.00
- Low price target
- kr 550.00
- Analysts with a price target
- 3
- Forward EPS
- kr 16.30
- EPS estimate, current year
- kr 12.50
Shares and trading
- Beta
- 1.39
- Average volume
- 63.9K
- Shares outstanding
- 17.16M
- Float
- 16.48M
- Institutional ownership
- 54.0%
- Insider ownership
- 3.7%